Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors

A. J. Melvin, S. Lennon, K. M. Mohan, Jonathan Purnell

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Our objective was to determine whether HIV-infected children treated with protease inhibitors (PIs) have different blood lipid, insulin, and glucose levels and body composition than HIV-infected children not treated with PIs. A cross-sectional cohort study was performed; in which 23 children were treated with combination antiretroviral therapy including a PI for at least 6 months and 12 children were treated with nucleoside reverse transcriptase inhibitors only (no-PI group). Levels of lipids, apolipoprotein B (apoB), insulin, and glucose were determined in the fasting state. Body composition and fat distribution were determined by anthropometric measurements and dual energy X-ray absorptiometry (DEXA) scan. Total cholesterol levels were higher in the PI-treated children (5.33 ± 0.87 mM) than in the no-PI children (3.69 ± 0.59 mM) (p <0.0001). Similarly, low-density lipoprotein (LDL) levels were also elevated in the PI-treated children (3.27 ± 0.76 vs. 2.14 ± 0.51 mM) (p <0.0001). ApoB and high-density lipoprotein (HDL), and to a lesser degree triglyceride levels, were also increased in the PI-treated children. Apart from percent arm fat as measured by DEXA, there were no differences between the two groups in measures of body composition or in their fasting glucose and insulin levels. The results from this cross-sectional cohort study suggest that the predominant lipid abnormalities associated with treatment with combination antiretroviral therapy including a PI in HIV-1-infected children are elevated total and LDL cholesterol.

Original languageEnglish (US)
Pages (from-to)1117-1123
Number of pages7
JournalAIDS Research and Human Retroviruses
Volume17
Issue number12
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Protease Inhibitors
HIV-1
Body Composition
Photon Absorptiometry
Apolipoproteins B
Lipids
Glucose
Fasting
Cohort Studies
Cross-Sectional Studies
HIV
Insulin
Body Fat Distribution
Reverse Transcriptase Inhibitors
HDL Lipoproteins
Hypercholesterolemia
LDL Lipoproteins
Nucleosides
LDL Cholesterol
Triglycerides

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors. / Melvin, A. J.; Lennon, S.; Mohan, K. M.; Purnell, Jonathan.

In: AIDS Research and Human Retroviruses, Vol. 17, No. 12, 2001, p. 1117-1123.

Research output: Contribution to journalArticle

@article{bd8a1ccb290c4cbcbfaca3d8efeab116,
title = "Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors",
abstract = "Our objective was to determine whether HIV-infected children treated with protease inhibitors (PIs) have different blood lipid, insulin, and glucose levels and body composition than HIV-infected children not treated with PIs. A cross-sectional cohort study was performed; in which 23 children were treated with combination antiretroviral therapy including a PI for at least 6 months and 12 children were treated with nucleoside reverse transcriptase inhibitors only (no-PI group). Levels of lipids, apolipoprotein B (apoB), insulin, and glucose were determined in the fasting state. Body composition and fat distribution were determined by anthropometric measurements and dual energy X-ray absorptiometry (DEXA) scan. Total cholesterol levels were higher in the PI-treated children (5.33 ± 0.87 mM) than in the no-PI children (3.69 ± 0.59 mM) (p <0.0001). Similarly, low-density lipoprotein (LDL) levels were also elevated in the PI-treated children (3.27 ± 0.76 vs. 2.14 ± 0.51 mM) (p <0.0001). ApoB and high-density lipoprotein (HDL), and to a lesser degree triglyceride levels, were also increased in the PI-treated children. Apart from percent arm fat as measured by DEXA, there were no differences between the two groups in measures of body composition or in their fasting glucose and insulin levels. The results from this cross-sectional cohort study suggest that the predominant lipid abnormalities associated with treatment with combination antiretroviral therapy including a PI in HIV-1-infected children are elevated total and LDL cholesterol.",
author = "Melvin, {A. J.} and S. Lennon and Mohan, {K. M.} and Jonathan Purnell",
year = "2001",
doi = "10.1089/088922201316912727",
language = "English (US)",
volume = "17",
pages = "1117--1123",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "12",

}

TY - JOUR

T1 - Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors

AU - Melvin, A. J.

AU - Lennon, S.

AU - Mohan, K. M.

AU - Purnell, Jonathan

PY - 2001

Y1 - 2001

N2 - Our objective was to determine whether HIV-infected children treated with protease inhibitors (PIs) have different blood lipid, insulin, and glucose levels and body composition than HIV-infected children not treated with PIs. A cross-sectional cohort study was performed; in which 23 children were treated with combination antiretroviral therapy including a PI for at least 6 months and 12 children were treated with nucleoside reverse transcriptase inhibitors only (no-PI group). Levels of lipids, apolipoprotein B (apoB), insulin, and glucose were determined in the fasting state. Body composition and fat distribution were determined by anthropometric measurements and dual energy X-ray absorptiometry (DEXA) scan. Total cholesterol levels were higher in the PI-treated children (5.33 ± 0.87 mM) than in the no-PI children (3.69 ± 0.59 mM) (p <0.0001). Similarly, low-density lipoprotein (LDL) levels were also elevated in the PI-treated children (3.27 ± 0.76 vs. 2.14 ± 0.51 mM) (p <0.0001). ApoB and high-density lipoprotein (HDL), and to a lesser degree triglyceride levels, were also increased in the PI-treated children. Apart from percent arm fat as measured by DEXA, there were no differences between the two groups in measures of body composition or in their fasting glucose and insulin levels. The results from this cross-sectional cohort study suggest that the predominant lipid abnormalities associated with treatment with combination antiretroviral therapy including a PI in HIV-1-infected children are elevated total and LDL cholesterol.

AB - Our objective was to determine whether HIV-infected children treated with protease inhibitors (PIs) have different blood lipid, insulin, and glucose levels and body composition than HIV-infected children not treated with PIs. A cross-sectional cohort study was performed; in which 23 children were treated with combination antiretroviral therapy including a PI for at least 6 months and 12 children were treated with nucleoside reverse transcriptase inhibitors only (no-PI group). Levels of lipids, apolipoprotein B (apoB), insulin, and glucose were determined in the fasting state. Body composition and fat distribution were determined by anthropometric measurements and dual energy X-ray absorptiometry (DEXA) scan. Total cholesterol levels were higher in the PI-treated children (5.33 ± 0.87 mM) than in the no-PI children (3.69 ± 0.59 mM) (p <0.0001). Similarly, low-density lipoprotein (LDL) levels were also elevated in the PI-treated children (3.27 ± 0.76 vs. 2.14 ± 0.51 mM) (p <0.0001). ApoB and high-density lipoprotein (HDL), and to a lesser degree triglyceride levels, were also increased in the PI-treated children. Apart from percent arm fat as measured by DEXA, there were no differences between the two groups in measures of body composition or in their fasting glucose and insulin levels. The results from this cross-sectional cohort study suggest that the predominant lipid abnormalities associated with treatment with combination antiretroviral therapy including a PI in HIV-1-infected children are elevated total and LDL cholesterol.

UR - http://www.scopus.com/inward/record.url?scp=0034827821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034827821&partnerID=8YFLogxK

U2 - 10.1089/088922201316912727

DO - 10.1089/088922201316912727

M3 - Article

C2 - 11522181

AN - SCOPUS:0034827821

VL - 17

SP - 1117

EP - 1123

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 12

ER -